STD 진단 시장 규모 : 제품 유형별, 검사 유형별, 질환별, 기술별, 최종 용도별, 예측(2024-2032년)

Global STD Diagnostics Market size will grow at a 7.2% CAGR from 2024 to 2032, fueled by technological advancements in diagnostics such as PCR and rapid testing solutions. These advancements improve the accuracy, speed, and accessibility of testing. Additionally, improved access to healthcare services, including point-of-care testing and telemedicine, encourages more individuals to seek STD diagnostics. As the global population grows and awareness increases, the combination of advanced technology and enhanced healthcare access will significantly expand the STD diagnostics industry, providing crucial tools for disease management and prevention.

For instance, in March 2023, BioPerfectus introduced an expanded range of PCR kits for STD diagnostics. The newly launched products include the Treponema Pallidum Real-Time PCR Kit and the Mycoplasma Hominis Real-Time PCR Kit, enhancing their diagnostic solutions for sexually transmitted diseases.

The STD diagnostics industry is segmented based on product type, test type, disease, technology, end-use, and region.

The molecular diagnostics segment will establish a substantial foothold by 2032, attributed to the segment's high accuracy, sensitivity, and ability to detect a wide range of sexually transmitted diseases (STDs). Molecular tests, such as PCR and nucleic acid amplification tests (NAATs), offer rapid and precise results, which are crucial for effective treatment and prevention. With rising STD prevalence globally and the demand for reliable diagnostics, the molecular diagnostics segment will dominate the market, providing vital tools for disease control and management.

The diagnostic laboratories segment will garner a significant STD diagnostics market share by 2032. These labs are pivotal due to their comprehensive range of tests, including molecular and culture-based methods. As primary testing hubs, they offer accessibility and expertise crucial for the early detection and treatment of STDs. With a growing emphasis on regular testing and screening, diagnostic laboratories will dominate the market, playing a vital role in public health initiatives and ensuring timely diagnosis and intervention.

Asia Pacific STD diagnostics industry will record a noteworthy CAGR by 2032, propelled by increasing awareness, rising STD prevalence, and improving healthcare infrastructure. Countries like China and India witness high demand for diagnostic services, fostering market growth. The region's focus on preventive healthcare and government initiatives for STD control contribute to this trend. With a burgeoning population and expanding access to healthcare, Asia Pacific will emerge as a notable contributor to the global STD diagnostics market, shaping its future landscape.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast calculations
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of sexually transmitted diseases
    • 3.2.1.2 Growing awareness and screening programs
    • 3.2.1.3 Increasing research and development activities
    • 3.2.1.4 Technological advancements in STD diagnostics
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stigma and sociocultural barriers
    • 3.2.2.2 Stringent regulatory scenario
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Instrument/analyzers
  • 5.2.1 Laboratory devices
    • 5.2.1.1 Thermal cyclers - PCR
    • 5.2.1.2 Lateral flow readers
    • 5.2.1.3 Flow cytometers
    • 5.2.1.4 Absorbance microplate reader
    • 5.2.1.5 Differential light scattering machines
    • 5.2.1.6 Other laboratory devices
  • 5.2.2 Point of care devices
    • 5.2.2.1 Phone chips (Microfludics + ICT)
    • 5.2.2.2 Portable/bench top/rapid diagnostic kits
• 5.3 Consumables

Chapter 6 Market Estimates and Forecast, By Test Type, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Laboratory testing
• 6.3 Point of care (PoC) testing

Chapter 7 Market Estimates and Forecast, By Disease, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG)
• 7.3 Syphilis
• 7.4 Gonorrhea
• 7.5 Genital herpes (HSV I & HSV II)
• 7.6 HPV (Human papillomavirus)
• 7.7 HIV/AIDS (Human immunodeficiency virus/ acquired immunodeficiency syndrome)
• 7.8 Ureaplasma & mycoplasma
• 7.9 Trichomoniasis
• 7.10 VZV (Varicella zoster virus)
• 7.11 Other diseases

Chapter 8 Market Estimates and Forecast, By Technology, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Immunoassay
• 8.3 Molecular diagnostics
• 8.4 Other technologies

Chapter 9 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospitals & clinics
• 9.3 Diagnostic laboratories
• 9.4 Home care testing
• 9.5 Other end-users

Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Italy
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
  • 10.5.4 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 South Africa
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Abbott Laboratories
• 11.2 Becton, Dickinson and Company
• 11.3 bioMerieux SA
• 11.4 Bio-Rad Laboratories, Inc.
• 11.5 Danaher Corporation
• 11.6 F. Hoffmann-La Roche Ltd
• 11.7 Hologic, Inc.
• 11.8 QIAGEN N.V.
• 11.9 Seegene Inc.
• 11.10 Siemens Healthineers AG
• 11.11 Thermo Fisher Scientific Inc.
• 11.12 Trinity Biotech plc